An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01588184
Recruitment Status : Active, not recruiting
First Posted : April 30, 2012
Last Update Posted : February 23, 2018
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This single-arm, open-label, multicenter extension study will provide continued bevacizumab therapy to participants with solid tumors who were previously enrolled in a Roche/Genentech sponsored study and who derived benefit from the bevacizumab therapy. Participants will receive the same dose and regimen of bevacizumab as used in the previous parent trial and continue this treatment until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.

Condition or disease Intervention/treatment Phase
Neoplasms Drug: Bevacizumab Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 93 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Arm, Open Label Multicentre Extension Study of Bevacizumab in Patients With Solid Tumours on Study Treatment With Bevacizumab, at the End of A F. Hoffmann-La Roche and/or Genentech Sponsored Study
Actual Study Start Date : July 19, 2012
Estimated Primary Completion Date : October 18, 2018
Estimated Study Completion Date : October 18, 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Bevacizumab
Participants will receive bevacizumab until progression of disease or unacceptable toxicity, withdrawal of consent or death whichever occurs first.
Drug: Bevacizumab
Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).
Other Name: Avastin

Primary Outcome Measures :
  1. Percentage of Participants With Adverse Events [ Time Frame: Baseline up to approximately 12 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participant is treated with bevacizumab at the end of the Roche/Genentech sponsored parent trial and continues to have benefit as judged by the investigator
  • Eligible for continuation of bevacizumab treatment at the end of a parent trial, according to parent trial protocol
  • Able to comply with this extension study protocol (MO25757)

Exclusion Criteria:

  • Evidence of disease progression assessed according to parent trial protocol during the screening phase for this extension study
  • Evidence of any adverse event potentially attributable to bevacizumab, for which the local label recommends permanent discontinuation
  • A treatment interruption with bevacizumab of more than 42 days since the last administration of bevacizumab in the parent trial
  • Evidence of any other disease that would put the participant at high risk for treatment-related complications

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01588184

  Show 74 Study Locations
Sponsors and Collaborators
Hoffmann-La Roche
Study Director: Clinical Trials Hoffmann-La Roche

Responsible Party: Hoffmann-La Roche Identifier: NCT01588184     History of Changes
Other Study ID Numbers: MO25757
2011-002009-31 ( EudraCT Number )
First Posted: April 30, 2012    Key Record Dates
Last Update Posted: February 23, 2018
Last Verified: February 2018

Additional relevant MeSH terms:
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents